Skip to main content

Table 1 Characteristics of studies reporting cancer-specific survival for endometrial cancer patients with diabetes compared to without

From: Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis

Author,
year and
location
Study design Study cohort source/database Endometrial cancer study population Recruitment period Study size Diabetes ascertainment No. of EC-specific deaths Risk estimate reported Outcome ascertainment Follow-up (mean/ median) NOS score
Bjornsdottir[56]
2020
Sweden
Population-based Swedish Cancer Registry NR 1998–2012 NR The Swedish National Diabetes Register NR HR The Total Population Register and Swedish Cause of Death Registry 6.6 years (median) 7
Brandt[51]
2019
U.S
Single institution-based Memorial Sloan Kettering Cancer Centre Stage I 2006–2016 1458 Medical records NR HR NR 2.4 years (median) 6
Donkers [57]
2021
U.K
Single institution-based Royal Cornwall Hospital Trust
Truro, Cornwall
High grade EC stages I-IV 2006–2017 176 Medical records 70 HR Medical records NR 8
Felix[34]
2015
U.S
Multi institution-based NRG Oncology/Gynecologic Oncology Group 210 molecular staging trial Stages I-IV 2003–2011 4109 Self-reported 582 HR Medical records and cancer registry 5 years (median) 6
Folsom[18]
2004
U.S
Population-based Iowa women’s health study and SEER cancer registry Stages I-IV 1986–2000 415 Self-reported 39 RR Registry, questionnaires and NDI 6.4 years (median) 6
Kolehmainen [59]
2020
Finland
Single institution-based Obstetrics and Gynaecology, Helsinki University Hospital Stages I-IV 2007–2012 515 Self-reported 97 HR Medical records and death certificates 6.75 years (median) 4
Lam[38]
2018
U.S
Population-based SEER database Stages I-IV 2000–2011 22,743 a b Medicare claims NR HR SEER database NR 8
Lees [53]
2021
U.S
Population-based Wisconsin Cancer Registry Stages I-IV 2006–2016 745 Structured interview 46 HR National death index 19.9 years (median) 8
Lindemann[17]
2015
Norway
Population-based Health surveys of North Trondelag (HUNT) Stages I-IV NR 337 Self-reported 56 HR Cancer registry 6.7 years (median) 5
Nagle[16]
2018
Australia
Population-based Australian National EC Study Stages I-IV 2005–2007 1359 Self-reported 123 HR Medical records and NDI 7.1 years (median) 6
Olson[21]
2012
U.S
Population-based SEER-Medicare database Stages I-IV 2000- 2005 958 c Medicare claims NR HR SEER registries 3.5 years (median) 6
Ribeiro [44]
2021
Brazil
Single institution-based Department of
Obstetrics and Gynaecology, University of Campinas, Sao Paulo
Non-endometrioid EC stages I-IV 2002–2017 127 Medical records NR HR Medical records 4.5 years (mean) 5
Ruterbusch[19]
2014
U.S
Single institution-based Henry Ford Health System (HFHS) tumor registry Stages I-IV 1990–2005 627 HFHS, medical records and the MDCSS 109 HR HFHS, medical records and the MDCSS NR 6
Simon [54]
2021
U.S
Population-based Women’s Health Initiative (WHI) Stages I-III 1993–1998 NR Self-report and medication use NR HR Medical records, death certificates,
relative’s report and NDI
10 years (median) 6
Sung[20]
2000
U.S. and China
Multi-institution-based Women & Infants’ Hospital of RI, Cornell University Medical Centre, Shanghai Medical University, and Women’s and Children’s Hospital, University of Southern California Stages I-IV 1976 to 1998 125 Medical records 112 RR Medical records and pathology reports 5.4 years (mean) 7
VanArsdale[15]
2019
U.S
Single institution-based Montefiore Medical Centre Stages I-IV 1999–2016 1,732 Medical records 393 HR Social security death index 3.4 years (median) 7
Zanders[58]
2013
Netherlands
Population-based Eindhoven cancer registry Endometrioid EC stages I-III 2000- 2008 388 Medical records NR HR Municipal personal records NR 8
  1. aIncluded all uterine cancer patients
  2. bOnly white patients included due to cohort overlap with Olson et al.[21]
  3. cOnly black patients included due to cohort overlap with Lam et al.[38]
  4. EC Endometrial cancer, NOS Newcastle Ottawa Scale, NDI National Death Index, SEER Surveillance, Epidemiology and End results program, MDCSS Metropolitan Detroit Cancer Surveillance System, NR Not reported, U.S. United States, RI Rhode Island, HR Hazard Ratio, RR Relative Risk